New Triple-Threat treatment tested for tough breast cancers
NCT ID NCT03685331
Summary
This study tested whether combining three medications—olaparib, palbociclib, and fulvestrant—is safe for people with advanced breast cancer that is hormone-sensitive and has a BRCA gene mutation. The main goal was to check for side effects and see how long patients lived without their cancer getting worse. It involved 9 adult participants who had not progressed on certain prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.